New drug combo aims to tame tough rheumatoid arthritis

NCT ID NCT05306353

First seen Feb 01, 2026 · Last updated May 09, 2026 · Updated 17 times

Summary

This study tested whether adding a 12-week course of VIB4920 to standard TNF-inhibitor therapy could improve disease control in people with rheumatoid arthritis who did not respond well to TNF-inhibitors alone. Only 2 participants were enrolled before the study was stopped. The goal was to reduce joint swelling and pain, but results are limited due to early termination.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Brigham & Women's Hospital: Department of Medicine, Rheumatology, Immunology

    Boston, Massachusetts, 02215, United States

  • Duke University Medical Center: Division of Rheumatology and Immunology

    Durham, North Carolina, 27710, United States

  • University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center

    San Francisco, California, 94110, United States

  • University of Colorado School of Medicine: Division of Rheumatology

    Aurora, Colorado, 80045, United States

  • University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology

    Ann Arbor, Michigan, 48109, United States

Conditions

Explore the condition pages connected to this study.